ABUS
Arbutus Biopharma Corporation NASDAQ Listed Jul 26, 2007$4.34
After hrs
$4.36
+0.45%
Mkt Cap $854.7M
52w Low $2.94
64.8% of range
52w High $5.10
50d MA $4.44
200d MA $4.27
P/E (TTM)
-25.4x
EV/EBITDA
-34.0x
P/B
10.8x
Debt/Equity
0.1x
ROE
-43.8%
P/FCF
-23.3x
RSI (14)
—
ATR (14)
—
Beta
0.74
50d MA
$4.44
200d MA
$4.27
Avg Volume
2.4M
Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical trial targeted to hepatocytes that inhibits viral replication and reduces various HBV antigens using novel covalently conjugated N-acetylgalactosamine (GalNAc) delivery technology; and AB-836, an oral capsid inhibitor that suppresses HBV DNA replication. The company's research and development programs include AB-161, an oral HBV RNA destabilizer to destabilize HBV RNA, which leads in the reduction of HBsAg and other viral proteins; AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune response; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has strategic alliance, licensing, and research collaboration agreements with Talon Therapeutics, Inc.; Gritstone Oncology, Inc.; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd.; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Vaccitech plc to evaluate a triple combination of AB-729 for the treatment of chronic HBV infection. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.
701 Veterans Circle · Warminster, PA 18974 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 23, 2026 | AMC | -0.04 | -0.01 | +71.3% | 4.42 | -2.3% | -2.5% | +2.5% | +0.7% | -2.9% | -2.7% | — |
| Nov 13, 2025 | AMC | -0.06 | -0.04 | +28.6% | 4.56 | -1.3% | -0.9% | -0.4% | -2.4% | -6.4% | -7.9% | — |
| Aug 6, 2025 | AMC | -0.02 | 0.01 | +150.0% | 3.47 | +1.7% | -2.0% | -2.0% | -3.5% | -2.0% | -2.9% | — |
| May 14, 2025 | AMC | -0.09 | -0.13 | -44.4% | 3.16 | -0.9% | -1.3% | -2.5% | -0.9% | +1.6% | +0.3% | — |
| Mar 27, 2025 | AMC | -0.08 | -0.07 | +12.5% | 3.27 | +0.0% | +7.0% | +6.7% | +6.4% | +7.3% | +7.3% | — |
| Nov 6, 2024 | AMC | -0.10 | -0.10 | +0.0% | 3.92 | +0.0% | -4.8% | -4.3% | -4.8% | -7.1% | -6.9% | — |
| Aug 1, 2024 | AMC | -0.10 | -0.11 | -10.0% | 3.81 | -3.1% | -1.8% | -5.0% | -5.0% | -7.9% | -5.5% | — |
| May 2, 2024 | AMC | -0.10 | -0.10 | +0.0% | 2.68 | +1.1% | +1.1% | +4.5% | +6.0% | +6.0% | +9.7% | — |
| Feb 29, 2024 | AMC | -0.12 | -0.12 | +0.0% | 2.80 | -0.7% | -0.4% | -3.2% | -4.6% | -2.1% | -3.6% | — |
| Nov 7, 2023 | AMC | -0.12 | -0.12 | +0.0% | 1.85 | +1.1% | +1.1% | -2.7% | -4.3% | -3.2% | +1.6% | — |
| Aug 3, 2023 | AMC | -0.12 | -0.10 | +16.7% | 2.06 | -0.5% | +3.9% | +1.9% | -1.5% | -1.5% | +0.0% | — |
| May 4, 2023 | AMC | -0.14 | -0.10 | +28.6% | 2.55 | +1.6% | +2.0% | +2.4% | +2.4% | +3.5% | +0.4% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nov 14 | Chardan Capital | Maintains | Buy → Buy | — | $4.56 | $4.50 | -1.3% | -0.9% | -0.4% | -2.4% | -6.4% | -7.9% |
| Aug 11 | Chardan Capital | Maintains | Buy → Buy | — | $3.40 | $3.40 | +0.0% | -1.5% | +0.0% | -0.9% | -0.9% | -0.9% |
| Mar 28 | Chardan Capital | Maintains | Buy → Buy | — | $3.27 | $3.27 | +0.0% | +7.0% | +6.7% | +6.4% | +7.3% | +7.3% |
| Jan 21 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.20 | $3.19 | -0.3% | +0.3% | +0.6% | +4.4% | +3.8% | +7.2% |
| Nov 20 | Chardan Capital | Maintains | Buy → Buy | — | $3.49 | $3.53 | +1.1% | -1.4% | -0.9% | +0.6% | -2.0% | -2.3% |
| Nov 18 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.64 | $3.64 | +0.0% | -3.3% | -4.1% | -5.5% | -4.9% | -3.6% |
| Nov 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.92 | $3.92 | +0.0% | -4.8% | -4.3% | -4.8% | -7.1% | -6.9% |
| Nov 6 | Chardan Capital | Maintains | Buy → Buy | — | $3.96 | $3.85 | -2.8% | -1.0% | -5.8% | -5.3% | -5.8% | -8.1% |
| Sep 5 | Jefferies | Maintains | Buy → Buy | — | $4.09 | $4.18 | +2.2% | +10.3% | +11.2% | +9.8% | +11.5% | +11.5% |
| Aug 2 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $3.81 | $3.69 | -3.1% | -1.8% | -5.0% | -5.0% | -7.9% | -5.5% |
| Jun 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.34 | $3.31 | -0.9% | -4.2% | -6.0% | -4.8% | -2.7% | -5.4% |
| Jun 6 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.63 | $3.63 | +0.0% | -8.0% | -11.8% | -13.5% | -12.4% | -10.5% |
| Jun 5 | Chardan Capital | Maintains | Buy → Buy | — | $3.34 | $3.38 | +1.2% | +8.7% | +0.0% | -4.2% | -6.0% | -4.8% |
| May 3 | Chardan Capital | Maintains | Buy → Buy | — | $2.68 | $2.71 | +1.1% | +1.1% | +4.5% | +6.0% | +6.0% | +9.7% |
| Apr 4 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $2.92 | $2.93 | +0.3% | +2.7% | +6.8% | +5.8% | +3.1% | +2.1% |
| Mar 1 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.80 | $2.78 | -0.7% | -0.4% | -3.2% | -4.6% | -2.1% | -3.6% |
| Mar 1 | Chardan Capital | Maintains | Buy → Buy | — | $2.80 | $2.78 | -0.7% | -0.4% | -3.2% | -4.6% | -2.1% | -3.6% |
| Sep 12 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.20 | $2.19 | -0.5% | -7.7% | -6.8% | -6.8% | -7.3% | -9.5% |
| Aug 4 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.06 | $2.05 | -0.5% | +3.9% | +1.9% | -1.5% | -1.5% | +0.0% |
| Aug 4 | Chardan Capital | Maintains | Buy → Buy | — | $2.06 | $2.05 | -0.5% | +3.9% | +1.9% | -1.5% | -1.5% | +0.0% |
| Jul 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.26 | $2.32 | +2.7% | +0.4% | +0.4% | +0.4% | -1.3% | -0.4% |
| Jul 6 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $2.26 | $2.25 | -0.4% | -1.3% | +0.0% | +0.0% | +0.4% | +0.4% |
| Jun 22 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.37 | $2.40 | +1.3% | +4.2% | +1.7% | -4.6% | -5.5% | -5.1% |
| Jun 22 | Chardan Capital | Maintains | Buy → Buy | — | $2.37 | $2.40 | +1.3% | +4.2% | +1.7% | -4.6% | -5.5% | -5.1% |
| May 5 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.55 | $2.59 | +1.6% | +2.0% | +2.4% | +2.4% | +3.5% | +0.4% |
| Apr 28 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.51 | $2.52 | +0.4% | +0.0% | +0.4% | -1.2% | +0.0% | +1.6% |
| Apr 5 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.99 | $3.00 | +0.3% | -3.0% | -4.0% | -4.0% | -2.7% | -6.0% |
| Mar 29 | JMP Securities | Maintains | Market Outperform → Outperform | — | $3.00 | $3.02 | +0.7% | +3.3% | +0.7% | +1.0% | +2.0% | -0.3% |
| Mar 20 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.99 | $3.02 | +1.0% | +1.0% | +1.3% | -1.3% | -1.0% | +0.3% |
| Mar 3 | Chardan Capital | Maintains | Buy → Buy | — | $2.81 | $2.80 | -0.4% | +1.8% | +2.5% | +4.3% | +5.0% | +0.7% |
| Mar 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.81 | $2.80 | -0.4% | +1.8% | +2.5% | +4.3% | +5.0% | +0.7% |
| Nov 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.44 | $2.50 | +2.5% | +1.6% | +4.9% | +8.2% | +14.3% | +10.7% |
| Jun 28 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $2.68 | $2.66 | -0.7% | -2.6% | +0.7% | +1.1% | +4.5% | +7.5% |
| Mar 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.91 | $2.94 | +1.0% | -3.4% | -1.7% | +2.4% | +3.8% | +5.2% |
| Mar 4 | Chardan Capital | Maintains | Buy → Buy | — | $2.95 | $2.93 | -0.7% | -4.7% | -4.1% | -2.4% | +8.1% | +4.7% |
| Feb 2 | Jefferies | Upgrade | Hold → Buy | — | $2.92 | $3.13 | +7.2% | -1.0% | -5.5% | +3.4% | +6.8% | +8.6% |
| Nov 8 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $3.48 | $3.50 | +0.6% | +3.4% | +0.6% | +0.0% | -0.3% | -0.3% |
| Dec 17 | H.C. Wainwright | Maintains | Buy → Buy | — | $4.41 | $5.08 | +15.2% | +7.3% | -1.4% | -3.6% | -8.4% | -8.2% |
| Jul 24 | Baird | Downgrade | Outperform → Neutral | — | $6.20 | $7.98 | +28.7% | -20.0% | -27.9% | -35.2% | -34.8% | -30.6% |
| May 19 | Wedbush | Upgrade | Neutral → Outperform | — | $1.87 | $2.69 | +43.9% | +23.5% | +26.2% | +25.1% | +22.5% | +18.2% |
| Mar 27 | Baird | Maintains | Outperform → Outperform | — | $2.26 | $2.00 | -11.5% | -46.5% | -50.4% | -55.3% | -53.1% | -55.8% |
| Mar 6 | Chardan Capital | Upgrade | Neutral → Buy | — | $3.00 | $3.25 | +8.3% | -1.0% | -8.0% | -7.3% | -14.0% | -23.0% |
| Feb 20 | Baird | Maintains | Outperform → Outperform | — | $3.27 | $3.47 | +6.1% | +4.6% | -0.6% | -7.3% | -8.3% | -14.4% |
| Feb 5 | JMP Securities | Upgrade | Market Perform → Market Outperform | — | $2.81 | $3.25 | +15.7% | +15.3% | +13.9% | +15.7% | +13.9% | +9.3% |
| Jan 9 | B. Riley FBR | Maintains | Buy → Buy | — | $3.07 | $3.10 | +1.0% | -4.6% | -1.3% | -3.9% | -2.3% | +0.0% |
| Jan 9 | B. Riley Securities | Maintains | Buy → Buy | — | $3.07 | $3.10 | +1.0% | -4.6% | -1.3% | -3.9% | -2.3% | +0.0% |
| Oct 4 | Chardan Capital | Downgrade | Buy → Neutral | — | $1.43 | $1.01 | -29.4% | -28.7% | -35.7% | -37.8% | -39.2% | -37.8% |
| Oct 16 | B. Riley FBR | Upgrade | Neutral → Buy | — | $4.14 | $4.43 | +7.0% | +12.3% | +13.8% | +7.2% | +4.8% | +4.8% |
| Oct 16 | B. Riley Securities | Upgrade | Neutral → Buy | — | $4.14 | $4.43 | +7.0% | +12.3% | +13.8% | +7.2% | +4.8% | +4.8% |
| Oct 15 | Wedbush | Upgrade | Underperform → Neutral | — | $4.31 | $4.69 | +8.8% | -3.9% | +7.9% | +9.3% | +3.0% | +0.7% |
No insider trades available.
8-K · 8.01
!! High
Unknown — 8-K 8.01: Material Event / Announcement
FDA Fast Track designation for imdusiran accelerates hepatitis B development timeline and potential market entry, improving commercialization prospects and de-risking the program for shareholders.
Apr 15
8-K
Unknown — 8-K Filing
Arbutus maintained disciplined spending and extended cash runway in Q4 2025, signaling management confidence in funding operations through key clinical milestones without dilutive financing.
Mar 23
8-K · 1.01
!! High
Unknown — 8-K 1.01: Material Agreement
Settlement with Moderna likely ends costly litigation risk for these biotech companies, potentially freeing resources for R&D and improving profit visibility going forward.
Mar 23
8-K · 8.01
!! High
Arbutus Biopharma Corporation -- 8-K 8.01: Material Event / Announcement
Arbutus Biopharma and Genevant entered a settlement agreement on March 3, 2026, resolving an unspecified dispute between the companies.
Mar 3
8-K · 8.01
!! High
Arbutus Biopharma Corporation -- 8-K 8.01: Material Event / Announcement
Arbutus Biopharma and licensee Genevant won a Delaware court ruling in their patent infringement litigation against Moderna, potentially securing damages for technology violations.
Feb 20
8-K · 8.01
!! High
Arbutus Biopharma Corporation -- 8-K 8.01: Material Event / Announcement
Arbutus Biopharma and its licensee Genevant won a Delaware court ruling against Moderna regarding patent infringement damages, potentially securing financial compensation for unauthorized use of their intellectual property.
Feb 6
Data updated apr 24, 2026 10:20am
· Source: massive.com